Citations

Mayo Clinic

Showing 10 of 108599 citations.

AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1
Neelapu, Sattva S. , Lekakis, Lazaros J. , Jacobson, Caron A. , Braunschweig, Ira , Timmerman, John M. , Navale, Lynn, Jiang, Yizhou , Aycock, Jeff, Elias, Meg , Wiezorek, Jeff, Go, William Y., Locke, Frederick L. , Bartlett, Nancy L. , Miklos, David B. , Oluwole, Olalekan O. , Siddiqi, Tanya , Lin, Yi , Reagan, Patrick Michael

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 28-28

10.1002/hon.2437_7 Get It

BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON‐BULKY HODGKIN LYMPHOMA: AN UPDATE FROM a PHASE 2 CLINICAL TRIAL
Park, S.I., Olajide, O , Reddy, Nashitha, Richards, Kristy L. , Deal, Allison M. , Noe, Jeanne F., Shea, Thomas C., Ansell, Steven M., Budde, Lihua E. , Ghosh, Nilanjan , Deal, Allison

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 81-82

10.1002/hon.2437_69 Get It

MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN‐FIXED, PARAFFIN‐EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT
Rosenwald, Andreas , Ott, German , Ramsower, Colleen , Braziel, Rita M., Weisenburger, Dennis D. , Chan, John, Cook, James R. , Fu, Kai , Greiner, Timothy C. , Smeland, Erlend B., Glinsmann‐Gibson, Betty, Gascoyne, Randy D. , Staudt, Louis M. , Mottok, Anja , Wright, George W. , Campo, Elı́as , Delabie, Jan , Song, Joo Y. , Chan, J.W., Holte, Harald , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Steidl, Christian , Rimsza, Lisa M.

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 59-60

10.1002/hon.2437_46 Get It

TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA
Boddicker, Rebecca L., Dasari, Surendra , Asmann, Yan W. , Knudson, Ryan A., Eckloff, Bruce W., Jen, Jin , Hu, Gangqing , Greipp, Patricia T. , Link, Brian K. , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L.

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 59-59

10.1002/hon.2437_45 Get It

GB VIRUS‐C (GBV‐C) INFECTION AND RISK OF LYMPHOMA: A CASE‐CONTROL STUDY FROM NORTH AMERICA
Allmer, Cristine, Xiang, Jinhua , Klinzman, Donna, Feldman, Anya, Nowakowski, Grzegorz S. , Liebow, Mark , Larson, Matthew , Call, Timothy G. , Famà, Angelo , Link, Brian K. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R. , Stapleton, Jack T.

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 55-56

10.1002/hon.2437_40 Get It

CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
Ghesquières, Hervé , Nicolas‐Virelizier, Emmanuelle , Thompson, C., Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Steven M., Sarkozy, Clémentine , Link, Brian K. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R. , Salles, Gilles

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 34-35

10.1002/hon.2437_15 Get It

Immunotherapy in lymphoma
Ansell, Stephen M. , Caligaris‐Cappio, Federico , Maloney, David G.

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S1 | Pages: 88-91

10.1002/hon.2408 | PMID 28591421 Get It

Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma
Kumar, Shaji , Laubach, Jacob P. , Giove, Thomas J., Quick, Maureen, Neuwirth, Rachel, Yung, Godwin , Richardson, Paul G. , Kumar, Shaji K , Rajkumar, S. Vincent , Richardson, Paul Gerard Guy , Yung, Godwin

British Journal of Haematology | June 7, 2017 | Volume: 178 | Issue: 5 | Pages: 756-763

10.1111/bjh.14754 | PMID 28591409 Get It

SummaryPeripheral neuropathy (PN) is the most troublesome adverse event associated with the proteasome inhibitor bortezomib. Studies suggest an inflammatory aetiology for bortezomib‐induced PN (BiPN) and it has been hypothesized that reducing inflammation with concomitant dexamethasone may reduce BiPN incidence and/or severity. We retrospectively analysed PN rates from 32 studies (2697 patients with previously untreated multiple myeloma) incorporating bortezomib and differing dexamethasone schedules: partnered dosing (days of and after bortezomib), weekly dosing, and other dosing schedules (e.g. days 1–4, 8–11). Pooled overall PN rates were 45·5%, 63·9%, and 47·5%, respectively, with 5·3%, 11·0%, and 9·6% grade ≥3. Adjusting for potential confounders (age, gender, presence of thalidomide, bortezomib treatment duration), PN rates in patients on partnered dosing schedules appeared lower than in patients on weekly or other dosing schedules. Analyses conducted using patient‐level data suggest that cumulative dexamethasone dose, a potential confounding factor, is unlikely to have influenced the analyses. Findings were similar in a separate pooled analysis excluding data from regimens incorporating thalidomide, when pooled overall PN rates were 50·1%, 63·9%, and 48·3%, respectively, with 4·2%, 11·0%, and 8·6% grade ≥3. These findings suggest that partnered dexamethasone dosing may result in less severe BiPN compared with alternative dexamethasone dosing schedules.
Supracondylar Fracture Practice Improvement Module
Stans, Anthony A. , Martin, David , Albanese, Stephen A.

Journal of Pediatric Orthopaedics | June 7, 2017 | Volume: 37 | Issue: 5 | Pages: e308-e308

10.1097/bpo.0000000000001040 | PMID 28594694 Get It